CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 5250
 
  
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 4202
 
  
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 392
 
  
 
C07K PEPTIDES 3133
 
  
 
A61B DIAGNOSIS; SURGERY; IDENTIFICATION 1239
 
  
 
A61M DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY 1153
 
  
 
C40B COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES, IN SILICO LIBRARIES 121
 
  
 
G06F ELECTRIC DIGITAL DATA PROCESSING 1446

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

  • No Recent Publications to Display

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
7932212 Inhibition of placenta growth factor (PlGF) mediated metastasis and/or angiogenesisNov 17, 09Apr 26, 11[C40B]
7683044 Sphingomyelin therapy of autoimmune diseaseSep 18, 07Mar 23, 10[A01N]
7642239 Inhibition of placenta growth factor (PLGF) mediated metastasis and/or angiogenesisOct 16, 06Jan 05, 10[A61K]
7465551 Method of determining cytokine dosage for improving myelosuppressive stateAug 07, 06Dec 16, 08[G01N]
7288534 Sphingomyelin enhancement of tumor therapyFeb 14, 03Oct 30, 07[A01N]
7279289 Method of evaluating myelosuppressive stateSep 14, 05Oct 09, 07[G01N]
7220399 Alpha or beta emitters attached to fragments in radioimmunotherapyDec 01, 03May 22, 07[A61K]
7112409 Method of determining cytokine dosage for myelosuppressive stateJun 14, 02Sep 26, 06[G01N]
6703488 Antibody/receptor targeting moiety for enhanced delivery of armed ligandJan 15, 99Mar 09, 04[C07K]
6667024 Alpha or beta emitters attached to fragments in radioimmunotherapyJun 07, 00Dec 23, 03[A61K]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2012/0321,556 Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-GammaAbandonedAug 06, 12Dec 20, 12[A61K, A61P]
2011/0189,268 Inhibition of Placenta Growth Factor (PLGF) Mediated Metastasis and/or AngiogenesisAbandonedMar 11, 11Aug 04, 11[A61K, B82Y, C12N, A61P, C07K]
2011/0171,126 Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-GammaAbandonedJan 11, 11Jul 14, 11[A61K, A61P]
2011/0064,754 Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus VaccinesAbandonedOct 29, 10Mar 17, 11[A61K, A61P, C07K]
2006/0217,425 Methods of treating cancer using PPAR-gamma antagonistsAbandonedMar 14, 06Sep 28, 06[A61K]
2006/0182,683 Methods for reduced renal uptake of protein conjugatesAbandonedJan 30, 06Aug 17, 06[A61K]
2004/0265,231 Use of antioxidants to mitigate radioimmunotherapy-induced radiation toxicityAbandonedJul 19, 04Dec 30, 04[A61K]
2004/0077,843 Antibody/receptor targeting moiety for enhanced delivery of armed ligandAbandonedNov 24, 03Apr 22, 04[C07K]
2003/0203,836 Methods for reduced renal uptake of protein conjugatesAbandonedMay 15, 03Oct 30, 03[A61K]
2002/0111,300 METHODS FOR REDUCED RENAL UPTAKE OF PROTEIN CONJUGATESAbandonedNov 30, 98Aug 15, 02[A61K, A01N, C07K]
5057313 Diagnostic and therapeutic antibody conjugatesExpiredAug 23, 88Oct 15, 91[A61K, C12N, C07K]
4859449 Modified antibodies for enhanced hepatocyte clearanceExpiredSep 14, 87Aug 22, 89[A61K]
4846187 Dual isotope scintigraphic image enhancementExpiredDec 01, 87Jul 11, 89[A61K, A61B]
4699784 Tumoricidal methotrexate-antibody conjugateExpiredFeb 25, 86Oct 13, 87[A61K, C07K]

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.